Antidote funding, valuation and financials

£2.4 M

Antidote Revenue FY, 2016

Antidote Gross profit (FY, 2016)1.3 M

Antidote Gross profit margin (FY, 2016), %53%

Antidote Net income (FY, 2016)-3.3 M

Antidote EBITDA (FY, 2016)-3.6 M

Antidote EBIT (FY, 2016)-3.7 M

Antidote Cash, 31-Dec-20162.3 M

Antidote revenue was £2.41 m in FY, 2016

Embed Graph

Founding Date	2009
Antidote total Funding	$17.9 m
Antidote latest funding size	$13.50 m
Time since last funding	3 years ago
Antidote investors	Amadeus Capital Partners, Smedvig Capital, Octopus Ventures

Antidote's latest funding round in February 2015 was reported to be $13.5 m. In total, Antidote has raised $17.9 m

Embed Graph

GBP	FY, 2012	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	284.3 k	1.9 m	147.5 k	1.3 m	2.3 m
Accounts Receivable	73.1 k	211.4 k	504.2 k	647.1 k	967.5 k
Current Assets	357.4 k	2.1 m	651.8 k	2.2 m	3.7 m
PP&E	1.5 k	6.7 k	14.9 k	85.5 k	77 k
Total Assets	388.1 k	2.1 m	666.7 k	2.4 m	3.9 m
Accounts Payable	23.9 k	61.6 k	1 m	226.3 k	77.5 k
Current Liabilities	23.9 k	61.6 k	1 m	442.1 k	638.8 k
Non-Current Liabilities				54 k	132.5 k
Total Liabilities	23.9 k	61.6 k	1 m	496 k	771.4 k
Additional Paid-in Capital	43 k	45.1 k	44.3 k	45 k	45.9 k
Retained Earnings				(2.2 m)	(3.3 m)
Total Equity	364.2 k	2.1 m	(363.4 k)	1.9 m	3.1 m
Financial Leverage	1.1 x	1 x	-1.8 x	1.3 x	1.2 x